FTC Would Get Green Light To Go After Patent Thickets Under Bipartisan Senate Bill
Legislation by Sens. Cornyn, R-TX, and Blumenthal, D-CT, in part reflects frustration over AbbVie’s tactics to preserve patent protection for Humira.
You may also be interested in...
Pfizer VP blames rebate strategies of innovators for difficulty in getting biosimilars on formularies while Express Scripts official says it is all about net cost during House hearing on lowering Rx drug prices.
US committee will likely re-examine the language regarding the burden of proof in a bill prohibiting pay-for-delay settlements.
Sen. Cornyn recommended the Judiciary Committee initiate an inquiry into drug patents after a back-and-forth with AbbVie CEO Gonzalez over the Humira patent estate at the drug pricing hearing.